| 2024/04/26 17:37:36 | |
|---|---|
| Price | |
| 11.70 EUR | |
| Difference | -1.27% (-0.15) |
General attributes
| ISIN | BE0974363955 |
| Symbol | 52U |
| Exchange | Euronext Brussels |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 202 EUR |
| Benchmark | BEL 20 INDEX |
Market data
| Bid (Bid size) | - (416) |
| Ask (Ask size) | - (24,100) |
| Open | 11.90 EUR |
| High | 11.90 EUR |
| Low | 11.70 EUR |
| Close (prev. day) | 11.85 EUR |
| VWAP | 11.762277 EUR |
| Volume (pcs) | 5,657 |
| Trading volume | 66,539.00 |
| Number of trades | 52 |
| Last size | 97 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: HYLORIS PHARMACEUTICALS SA |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/06/21 |
|
Global Equity Ratings |
|
| 2024/06/14 |
|
Global Equity Ratings |
|
| 2024/05/29 |
|
Global Equity Ratings |
|
| 2024/04/26 |
|
Global Equity Ratings |
|
| 2024/04/03 |
|
Global Equity Ratings |
|
| 2024/04/26 17:37:36 | |
|---|---|
| Price | |
| 11.70 EUR | |
| Difference | -1.27% (-0.15) |
General attributes
| ISIN | BE0974363955 |
| Symbol | 52U |
| Exchange | Euronext Brussels |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 202 EUR |
| Benchmark | BEL 20 INDEX |
Market data
| Bid (Bid size) | - (416) |
| Ask (Ask size) | - (24,100) |
| Open | 11.90 EUR |
| High | 11.90 EUR |
| Low | 11.70 EUR |
| Close (prev. day) | 11.85 EUR |
| VWAP | 11.762277 EUR |
| Volume (pcs) | 5,657 |
| Trading volume | 66,539.00 |
| Number of trades | 52 |
| Last size | 97 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -5.65% | -8.95% | -9.30% |
| Perf (abs.) | -0.70 | -1.15 | -1.20 |
| Beta | -0.12 | 0.13 | 0.15 |
| Volatility | 35.39 | 33.36 | 33.04 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 11.83 EUR (6,279) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 11.84 EUR (14,992) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 12.32 EUR (11,731) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 12.01 EUR (7,711) |
| YTD High | date | 13.30 EUR (2024/01/03) |
| YTD Low | date | 11.00 EUR (2024/03/22) |
| 52 Weeks High | date | 14.10 EUR (2023/10/18) |
| 52 Weeks Low | date | 10.60 EUR (2023/12/20) |
All listings for HYLORIS PHARMACEUTICALS SA
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Stuttgart | 2024/04/29 | 08:08 | 11.55 EUR | 0.00 | 3 |
| London Stock Exchange | - | - | - | 0.00 | - |
| Frankfurt | 2024/04/29 | 08:22 | 11.40 EUR | 0.00 | 2 |
| Euronext Brussels | 2024/04/26 | 17:37 | 11.70 EUR | 0.07 | 52 |
| Duesseldorf | 2024/04/29 | 08:12 | 11.50 EUR | 0.00 | 1 |
Company Logo
Contact Details
| HYLORIS PHARMACEUTICALS SA |
| - - |
| Boulevard Patience et Beaujonc N°3/1 - 4000 Liege |
| Telefon: +32-4-346-02-07 |
| Fax: + |
| E-mail: contact@hyloris.com |
PDF Downloads
| Company report: HYLORIS PHARMACEUTICALS SA | |
Company Profile
Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. It offers commercial-stage products, Sotalol IV for the treatment of atrial fibrillation; and Maxigesic IV, a novel, dual modeof-action non-opioid analgesic for the treatment of post-operative pain. The company was founded by Stijn van Rompay and Thomas Jacobsen in 2012 and is headquartered in Liege, Belgium. |
Members of Management Board
| Stijn van Rompay | Chairman of Managing Board |
| Dietmar Aichhorn | Member of Executive Committee |
| Jean-Luc Vandebroek | Member of Executive Committee |
| Koenraad van der Elst | Member of Executive Committee |
| Thomas Jacobsen | Member of Executive Committee |
Board of directors
| Stefan Yee | Chairman of Supervisory Board |
| Carolyn Myers | Member of Supervisory Board |
| Chris Buyse | Member of Supervisory Board |
| James Gale | Member of Supervisory Board |
| Leon van Rompay | Member of Supervisory Board |
| Marc Foidart | Member of Supervisory Board |
| Thomas Jacobsen | Member of Supervisory Board |